0.3603
price up icon4.54%   0.0115
 
loading
Precedente Chiudi:
$0.3488
Aprire:
$0.34
Volume 24 ore:
212.09K
Relative Volume:
1.13
Capitalizzazione di mercato:
$22.98M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.3079
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+20.75%
1M Prestazione:
+8.53%
6M Prestazione:
-27.79%
1 anno Prestazione:
-70.11%
Intervallo 1D:
Value
$0.34
$0.3798
Intervallo di 1 settimana:
Value
$0.2774
$0.3798
Portata 52W:
Value
$0.257
$1.33

Passage Bio Inc Stock (PASG) Company Profile

Name
Nome
Passage Bio Inc
Name
Telefono
(267) 866-0312
Name
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
Dipendente
60
Name
Cinguettio
@passage_bio
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
PASG's Discussions on Twitter

Confronta PASG con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PASG
Passage Bio Inc
0.3697 18.48M 0 -68.80M -59.06M -1.17
Biotechnology icon
ONC
Beigene Ltd Adr
241.49 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.01 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.92 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.88 5.92B 0 -153.72M -103.81M -2.00

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-29 Ripresa Wedbush Outperform
2024-09-03 Iniziato Rodman & Renshaw Buy
2022-03-08 Downgrade JP Morgan Overweight → Neutral
2022-01-19 Downgrade Goldman Buy → Neutral
2021-07-01 Iniziato Raymond James Outperform
2021-06-15 Iniziato BTIG Research Buy
2021-03-04 Aggiornamento Goldman Neutral → Buy
2021-02-04 Iniziato Guggenheim Buy
2021-01-25 Iniziato Wedbush Outperform
2021-01-04 Aggiornamento JP Morgan Neutral → Overweight
2020-12-11 Iniziato Citigroup Neutral
2020-08-14 Downgrade JP Morgan Overweight → Neutral
2020-06-25 Downgrade Goldman Buy → Neutral
2020-03-25 Iniziato Chardan Capital Markets Buy
2020-03-24 Iniziato Cowen Outperform
2020-03-24 Iniziato Goldman Buy
2020-03-24 Iniziato JP Morgan Overweight
Mostra tutto

Passage Bio Inc Borsa (PASG) Ultime notizie

pulisher
May 20, 2025

Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com

May 20, 2025
pulisher
May 20, 2025

GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com

May 20, 2025
pulisher
May 20, 2025

Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG Stock News - GuruFocus

May 20, 2025
pulisher
May 18, 2025

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN

May 18, 2025
pulisher
May 18, 2025

Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World

May 18, 2025
pulisher
May 16, 2025

Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com

May 16, 2025
pulisher
May 16, 2025

Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World

May 16, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 14, 2025

Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech

May 14, 2025
pulisher
May 14, 2025

Passage Bio Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Passage BIO, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times

May 13, 2025
pulisher
May 11, 2025

Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 08, 2025

2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace

May 08, 2025
pulisher
Apr 30, 2025

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus

Apr 30, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 11, 2025

Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter

Apr 11, 2025
pulisher
Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025
pulisher
Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025
pulisher
Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025

Passage Bio Inc Azioni (PASG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$4.10
price down icon 2.24%
$288.77
price down icon 0.25%
$72.94
price down icon 0.11%
Capitalizzazione:     |  Volume (24 ore):